Literature DB >> 11130881

Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence.

K Van Herck1, P Van Damme.   

Abstract

To estimate the long-term persistence of anti-HAV antibodies, 120 (schedule 0-6) and 194 (schedule 0-12) adults were vaccinated and followed-up annually for 6 years. Shortly after the last dose, anti-HAV levels fell sharply (annual decline rate delta > 65%). Thereafter, delta diminished to 10-15%. GMTs 5.5 years after the last dose were 522 mIU/ml (0-6 group) and 749 mIU/ml (0-12 group); all subjects except one maintained detectable antibodies. The average delta over the whole follow-up period was 15-20%, resulting in an estimated persistence of anti-HAV levels > or =20 mIU/ml for 20-25 years. These estimates were similar for both applied calculation methods (GMT or individual based) and both vaccination schedules. Because the individual antibody levels tended to stabilise between the last two measurements, the hypothesis of a slow, log-linear decrease and its matching calculation methods might be subject to reconsideration. With the current methodology, however, detectable antibodies are estimated to persist for 20-25 years.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11130881

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  22 in total

Review 1.  The place of accelerated schedules for hepatitis A and B vaccinations.

Authors:  Jane Zuckerman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study.

Authors:  Filippo Ansaldi; Bianca Bruzzone; Maria Cristina Rota; Antonino Bella; Marta Ciofi degli Atti; Paolo Durando; Roberto Gasparini; Giancarlo Icardi
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

3.  Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of age.

Authors:  Vincent Gajdos; Benoit Soubeyrand; Emmanuel Vidor; Patrick Richard; Julie Boyer; Christine Sadorge; Anne Fiquet
Journal:  Hum Vaccin       Date:  2011-05-01

4.  Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.

Authors:  Yunda Huang; Lily Zhang; Holly Janes; Nicole Frahm; Abby Isaacs; Jerome H Kim; David Montefiori; M Julie McElrath; Georgia D Tomaras; Peter B Gilbert
Journal:  Vaccine       Date:  2017-01-25       Impact factor: 3.641

5.  Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland.

Authors:  Pierre Alex Crisinel; Klara Maria Posfay-Barbe; Christoph Aebi; Jean-Jacques Cheseaux; Christian Kahlert; Christoph Rudin; David Nadal; Claire-Anne Siegrist
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

Review 6.  Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive®.

Authors:  Jun-Yu Wu; Yan Liu; Jiang-Ting Chen; Ming Xia; Xiao-Mei Zhang
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

7.  The prevalence of hepatitis A in children in British Columbia.

Authors:  Jan J Ochnio; David W Scheifele; Murray Fyfe; Mark Bigham; David Bowering; Paul Martiquet; Margaret Ho; Douglas N Talling
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-05       Impact factor: 2.471

Review 8.  Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data.

Authors:  E Vidor; R Dumas; V Porteret; F Bailleux; K Veitch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

Review 9.  Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability.

Authors:  David L Murdoch; Karen Goa; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up.

Authors:  Philip R Spradling; Lisa R Bulkow; Susan E Negus; Chriss Homan; Michael G Bruce; Brian J McMahon
Journal:  Hepatology       Date:  2016-02-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.